Merck & Co. said a European Medicines Agency panel recommended expanded approval of the drugmaker's blockbuster cancer treatment Keytruda in two types of gynecologic cancers.

The program gives manufacturers better access to regulators and the ability to design more flexible clinical trials.

Investorideas.com ( a go-to investing platform, releases the second of a two-part series looking at news and developments for the treatment of cancer and solid tumors focusing on immunotherapy, ...

The FDA's breakthrough tag is given to certain medical devices that provide treatment or diagnosis of life-threatening ...

According to Biospace.com "The solid tumors market size reached a value of US$ 170.3 Billion in 2023. Looking forward, the market is expected to reach US$ 375.4 Billion by 2034, exhibiting a growth ...

Merck and Siemens have signed a strategic partnership to accelerate digital transformation in manufacturing through smart, ...